Impact of histamine type-2 receptor antagonists on the anticancer efficacy of gefitinib in patients with non-small cell lung cancer
Autor: | Hirotoshi Dosaka-Akita, Naofumi Shinagawa, Masaki Kobayashi, Yoh Takekuma, Yasushi Shimizu, Mitsuru Sugawara, Ichiro Kinoshita, Ken Iseki, Yoshitaka Saito |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male Oncology medicine.medical_specialty Lung Neoplasms Histamine type-2 receptor antagonists (H2RAs) EGFR Antineoplastic Agents 030226 pharmacology & pharmacy 03 medical and health sciences 0302 clinical medicine Gefitinib Non-small cell lung cancer Carcinoma Non-Small-Cell Lung Internal medicine medicine Clinical endpoint Humans Drug Interactions Pharmacology (medical) 030212 general & internal medicine Epidermal growth factor receptor Adverse effect Lung cancer neoplasms Aged Retrospective Studies Aged 80 and over Pharmacology biology business.industry Hazard ratio Cancer General Medicine Middle Aged medicine.disease Progression-Free Survival respiratory tract diseases Acid suppressants (AS) Survival Rate Histamine H2 Antagonists Concomitant biology.protein Female Antacids business medicine.drug |
Zdroj: | European Journal of Clinical Pharmacology. 77:381-388 |
ISSN: | 0031-6970 |
Popis: | Purpose Gefitinib is one of the standard treatments for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutations. It has been reported that acid suppressants (AS) decrease the anti-tumor effect of gefitinib by reducing its solubility. AS is sometimes necessary in cancer patients; however, previous reports have not shown the most compatible AS with gefitinib administration in cancer patients. This study was conducted to determine if histamine type 2 receptor antagonists (H2RAs) can affect the anti-tumor efficacy of gefitinib. Methods Eighty-seven patients with NSCLC who were administered gefitinib were retrospectively investigated. Patients who were co-administered H2RA were compared with non-AS control patients. H2RA was administered once a day at about 3-5 or 8-12 h after gefitinib intake. The primary endpoint of this study was progression-free survival (PFS), and secondary endpoints were overall survival (OS), overall response rate (ORR), and adverse effects. Results Median PFS in H2RA group and control group was 8.0 months and 9.0 months, respectively, with no significant difference (p = 0.82). The incidence of liver dysfunction was significantly less in patients administered H2RA, whereas there were no differences between the two groups with regard to skin toxicity and diarrhea. Multivariate analysis suggested that H2RA co-administration is not a risk factor for worse PFS and OS (hazard ratio of 0.95, 0.86; 95% confidence interval of 0.60-1.48, 0.52-1.43;p = 0.82 and 0.60, respectively). Conclusion This study demonstrated that concomitant administration of H2RA with gefitinib does not affect the efficacy of gefitinib. |
Databáze: | OpenAIRE |
Externí odkaz: |